Relief Therapeutics Holding AG
RLFTD · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.02 | 0.01 | -0.00 |
| FCF Yield | 0.99% | -9.22% | -22.17% | -32.61% |
| EV / EBITDA | -1.53 | -10.36 | -0.48 | -0.40 |
| Quality | ||||
| ROIC | -6.07% | -6.98% | -10.29% | -8.49% |
| Gross Margin | -63.33% | -16.18% | -170.76% | -189.18% |
| Cash Conversion Ratio | -0.03 | 0.68 | 0.17 | 0.19 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,435,593.38% | 194.30% | 177.48% | 179.84% |
| Free Cash Flow Growth | 110.87% | 55.50% | 34.19% | -10.73% |
| Safety | ||||
| Net Debt / EBITDA | 0.91 | 3.30 | 0.22 | 0.13 |
| Interest Coverage | -129.21 | -98.80 | -110.11 | -130.85 |
| Efficiency | ||||
| Inventory Turnover | 4.45 | 17.34 | 14.63 | 19.43 |
| Cash Conversion Cycle | 53.02 | 34.63 | 79.66 | 43.83 |